<DOC>
	<DOC>NCT00791427</DOC>
	<brief_summary>This is an open-label study assessing electrophysiologic testing of the retina with Electoretinogram (ERG) /Electrooculogram (EOG) tests in patients with exudative age-related macular degeneration (AMD). The standard FDA-approved treatment for wet AMD is ranibizumab (Lucentis). This study focuses on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD.</brief_summary>
	<brief_title>ERG/EOG Study in AMD Patients Treated With Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study Age &gt;55 years Patients to be included in the study must have AMD with choroidal neovascularization BCVA between 20/20 20/400 Lesion size less than or equal to 12 MPS disc areas Prior treatment with an antiVEGF agent within 6 months of enrollment in this study Pregnancy (positive pregnancy test) Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch Prior enrollment in the study Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial Media insufficient to obtain a view Other causes of CNV not related to AMD Active ocular or periocular infection Ocular surgery within 1 month prior to the study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>